Compare MUJ & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MUJ | ANL |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.6M | 731.6M |
| IPO Year | 1998 | 2022 |
| Metric | MUJ | ANL |
|---|---|---|
| Price | $12.31 | $10.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 91.2K | ★ 127.0K |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.66 | $0.88 |
| 52 Week High | $12.68 | $17.25 |
| Indicator | MUJ | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 47.61 |
| Support Level | $11.96 | $9.46 |
| Resistance Level | $12.43 | $12.32 |
| Average True Range (ATR) | 0.11 | 1.22 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 66.67 | 50.19 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.